Clinical trial

Effects of botulinum toxin on levator ani syndrome - A double-blind, placebo-controlled study

Satish Sanku Chander Rao, J. Paulson, M. Mata, B. Zimmerman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background Levator ani syndrome is characterized by anorectal discomfort/pain, treatment of which is unsatisfactory. We hypothesized that Botulinum toxin relieves spasm and improves symptoms. Aim To perform a randomized, placebo-controlled, crossover study to examine the efficacy and safety of botulinum toxin in patients with levator ani syndrome. Methods Twelve patients with levator ani syndrome (≥1 year) received anal intra sphincteric injections of 100 units of botulinum toxin A and placebo at 90-day intervals using EMG guidance. Daily frequency, severity, duration and intensity of pain (VAS) were recorded. Anorectal manometry, balloon expulsion and pudendal nerve latency tests were performed to examine the physiological changes and adverse effects. Results Seven patients (male/female = 4/3) completed the study and three had incomplete data, but all 10 underwent in an ITT analysis; two others dropped out. After administration of botulinum toxin, the mean frequency, intensity and duration of pain were unchanged (P = 0.31) compared with baseline. The 90-day mean VAS pain score was 6.79 ± 0.27 vs. baseline score of 7.08 ± 0.29 (P = 0.25). Anal sphincter pressures, rectal sensory thresholds, pudendal nerve latency and balloon expulsion times were unchanged after drug or placebo administration. Conclusions Injection of botulinum toxin into anal sphincter is safe, but it does not improve anorectal pain in levator ani syndrome.

Original languageEnglish (US)
Pages (from-to)985-991
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume29
Issue number9
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Botulinum Toxins
Placebos
Clinical Trials
Pain
Pudendal Nerve
Anal Canal
Sensory Thresholds
Type A Botulinum Toxins
Injections
Manometry
Spasm
Cross-Over Studies
Levator syndrome
Safety
Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical trial : Effects of botulinum toxin on levator ani syndrome - A double-blind, placebo-controlled study. / Rao, Satish Sanku Chander; Paulson, J.; Mata, M.; Zimmerman, B.

In: Alimentary Pharmacology and Therapeutics, Vol. 29, No. 9, 01.05.2009, p. 985-991.

Research output: Contribution to journalArticle

@article{604e396cf9ba41e79651fa6f7f4f7470,
title = "Clinical trial: Effects of botulinum toxin on levator ani syndrome - A double-blind, placebo-controlled study",
abstract = "Background Levator ani syndrome is characterized by anorectal discomfort/pain, treatment of which is unsatisfactory. We hypothesized that Botulinum toxin relieves spasm and improves symptoms. Aim To perform a randomized, placebo-controlled, crossover study to examine the efficacy and safety of botulinum toxin in patients with levator ani syndrome. Methods Twelve patients with levator ani syndrome (≥1 year) received anal intra sphincteric injections of 100 units of botulinum toxin A and placebo at 90-day intervals using EMG guidance. Daily frequency, severity, duration and intensity of pain (VAS) were recorded. Anorectal manometry, balloon expulsion and pudendal nerve latency tests were performed to examine the physiological changes and adverse effects. Results Seven patients (male/female = 4/3) completed the study and three had incomplete data, but all 10 underwent in an ITT analysis; two others dropped out. After administration of botulinum toxin, the mean frequency, intensity and duration of pain were unchanged (P = 0.31) compared with baseline. The 90-day mean VAS pain score was 6.79 ± 0.27 vs. baseline score of 7.08 ± 0.29 (P = 0.25). Anal sphincter pressures, rectal sensory thresholds, pudendal nerve latency and balloon expulsion times were unchanged after drug or placebo administration. Conclusions Injection of botulinum toxin into anal sphincter is safe, but it does not improve anorectal pain in levator ani syndrome.",
author = "Rao, {Satish Sanku Chander} and J. Paulson and M. Mata and B. Zimmerman",
year = "2009",
month = "5",
day = "1",
doi = "10.1111/j.1365-2036.2009.03964.x",
language = "English (US)",
volume = "29",
pages = "985--991",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Clinical trial

T2 - Effects of botulinum toxin on levator ani syndrome - A double-blind, placebo-controlled study

AU - Rao, Satish Sanku Chander

AU - Paulson, J.

AU - Mata, M.

AU - Zimmerman, B.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background Levator ani syndrome is characterized by anorectal discomfort/pain, treatment of which is unsatisfactory. We hypothesized that Botulinum toxin relieves spasm and improves symptoms. Aim To perform a randomized, placebo-controlled, crossover study to examine the efficacy and safety of botulinum toxin in patients with levator ani syndrome. Methods Twelve patients with levator ani syndrome (≥1 year) received anal intra sphincteric injections of 100 units of botulinum toxin A and placebo at 90-day intervals using EMG guidance. Daily frequency, severity, duration and intensity of pain (VAS) were recorded. Anorectal manometry, balloon expulsion and pudendal nerve latency tests were performed to examine the physiological changes and adverse effects. Results Seven patients (male/female = 4/3) completed the study and three had incomplete data, but all 10 underwent in an ITT analysis; two others dropped out. After administration of botulinum toxin, the mean frequency, intensity and duration of pain were unchanged (P = 0.31) compared with baseline. The 90-day mean VAS pain score was 6.79 ± 0.27 vs. baseline score of 7.08 ± 0.29 (P = 0.25). Anal sphincter pressures, rectal sensory thresholds, pudendal nerve latency and balloon expulsion times were unchanged after drug or placebo administration. Conclusions Injection of botulinum toxin into anal sphincter is safe, but it does not improve anorectal pain in levator ani syndrome.

AB - Background Levator ani syndrome is characterized by anorectal discomfort/pain, treatment of which is unsatisfactory. We hypothesized that Botulinum toxin relieves spasm and improves symptoms. Aim To perform a randomized, placebo-controlled, crossover study to examine the efficacy and safety of botulinum toxin in patients with levator ani syndrome. Methods Twelve patients with levator ani syndrome (≥1 year) received anal intra sphincteric injections of 100 units of botulinum toxin A and placebo at 90-day intervals using EMG guidance. Daily frequency, severity, duration and intensity of pain (VAS) were recorded. Anorectal manometry, balloon expulsion and pudendal nerve latency tests were performed to examine the physiological changes and adverse effects. Results Seven patients (male/female = 4/3) completed the study and three had incomplete data, but all 10 underwent in an ITT analysis; two others dropped out. After administration of botulinum toxin, the mean frequency, intensity and duration of pain were unchanged (P = 0.31) compared with baseline. The 90-day mean VAS pain score was 6.79 ± 0.27 vs. baseline score of 7.08 ± 0.29 (P = 0.25). Anal sphincter pressures, rectal sensory thresholds, pudendal nerve latency and balloon expulsion times were unchanged after drug or placebo administration. Conclusions Injection of botulinum toxin into anal sphincter is safe, but it does not improve anorectal pain in levator ani syndrome.

UR - http://www.scopus.com/inward/record.url?scp=63849112846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849112846&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.03964.x

DO - 10.1111/j.1365-2036.2009.03964.x

M3 - Article

VL - 29

SP - 985

EP - 991

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -